
Please try another search
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
Name | Age | Since | Title |
---|---|---|---|
Susan K. Benton | 60 | 2020 | Independent Director |
Adrienne Lee Graves | 72 | 2024 | Independent Director |
George Magrath | 40 | 2023 | CEO & Director |
Jean E. Bennett | 70 | 2024 | Director |
Mark Pennesi | - | - | Member of Medical Advisory Board |
Sean Ainsworth | 56 | 2020 | Lead Independent Director |
James S. J. Manuso | 76 | 2020 | Independent Director |
Richard J. Rodgers | 58 | 2020 | Independent Director |
David S. Boyer | - | - | Member of Medical Advisory Board |
Cameron S. Gallagher | 54 | 2020 | Independent Chairman |
Arshad M. Khanani | 46 | 2024 | Member of Medical Advisory Board |
Christine Kay | - | - | Member of Medical Advisory Board |
Benjamin R. Yerxa | 59 | 2024 | President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review